RT Journal Article
SR Electronic
T1 New agents for the treatment of ovarian cancer: the next generation
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 252
OP 257
DO 10.1136/ijgc-00009577-200511001-00012
VO 15
IS Suppl 3
A1 J. DUPONT
A1 C. AGHAJANIAN
A1 P. SABBATINI
A1 D. R. SPRIGGS
YR 2005
UL http://ijgc.bmj.com/content/15/Suppl_3/252.abstract
AB Ovarian cancer shares many important characteristics with more common malignancies including breast, lung, and colon cancer. The relative chemosensitivity of ovarian cancer and other aspects of its unique biology provide opportunities for novel interventions. In this brief summary, some of the potential targets in ovarian cancer are discussed, including the HER kinases, heat shock protein, the 26S proteasome, and the angiogenesis pathway. The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next decade promises to be filled the therapeutic advances for patients with ovarian cancer.